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Abstract
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In girls and young women, irradiation of the ovaries can reduce the number of viable ovarian
primordial follicles, which may lead to premature ovarian failure and subsequently to sterility.
One strategy to minimize this late effect is to reduce the radiation dose to the ovaries. A primary
means of reducing dose is to choose a radiotherapy technique that avoids irradiating nearby
normal tissue; however, the relative risk of premature ovarian failure (RRPOF) due to the various
therapeutic options has not been assessed. This study compared the predicted RRPOF after
craniospinal proton radiotherapy, conventional photon radiotherapy, and intensity-modulated
photon radiotherapy. We calculated the equivalent dose delivered to the ovaries of an 11-year old
girl from therapeutic and stray radiation. We then predicted the percentage of ovarian primordial
follicles killed by radiation and used this as a measure of RRPOF; we also calculated the ratio of
relative risk of premature ovarian failure (RRRPOF) among the three radiotherapies. Proton
radiotherapy had a lower RRPOF than either of the other two types. We also tested the sensitivity
of the RRRPOF between photon and proton therapies to the anatomic position of the ovaries, i.e.,
proximity to the treatment field (2 ≤ RRRPOF ≤ 10). We found that CRT and IMRT have higher
risks of POF than PRT does, regardless of uncertainties in ovarian location. Over all PRT
represents a lower RRPOF over the two other modalities.

1. Introduction
Cancer is the second leading cause of death for children 1–14 years old in the United States,
and during the period from 1973 to 2000, approximately 40% of pediatric cancer patients
received radiotherapy as their initial cancer treatment (Jemal et al., 2009; Socie et al., 2000).
In the past decade, the overall 5-year survival rate of pediatric cancer patients has increased
to 80%. Higher survival rates have led to increased concerns about the risk of late effects
from radiation (Robison et al., 2009; Davis et al., 1999). For instance, children with
medulloblastoma who undergo craniospinal irradiation (CSI) have a 2–13% probability of
developing a radiogenic cancer such as meningioma, ovarian leiomyosarcoma, glioblastoma,
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acute lymphoblastic leukemia, or rectal adenocarcinoma sometime after radiation therapy
(Hope et al., 2006; Strojan et al., 2000; Stavrou et al., 2001; Fossati et al., 2009).
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One complication of radiotherapy is that direct irradiation of the ovaries can lead to acute
ovarian failure. A recent study found that 90% of patients whose ovaries received 14.4 Gy
during whole-body irradiation experienced acute ovarian failure (Sauvat et al., 2009). In
addition, irradiation of the ovaries can reduce the number of ovarian primordial follicles,
which may lead to premature ovarian failure and subsequently to sterility. Wallace et al.
(2003) determined that even a dose of 2 Gy can eradicate 50% of ovarian primordial
follicles. Thus, radiotherapy for all premenopausal female patients should include efforts to
carefully manage ovarian dose. Although many girls and young women undergo
radiotherapy, to our knowledge no study has compared the risk of fertility complications
after proton and photon therapies for central nervous system tumors.
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The goal of this study was to compare the relative risk of premature ovarian failure (RRPOF)
for three CSI radiotherapy modalities to predict which one would best preserve fertility. We
used clinically realistic and physically complete radiation doses and the model of Wallace et
al. (2005) to derive the RRPOF after conventional photon radiotherapy (CRT), intensitymodulated photon radiotherapy (IMRT), and passive-scattering proton radiotherapy (PRT).
We also calculated the ratio of the relative risk of premature ovarian failure (RRRPOF) of
PRT to CRT and IMRT.

2. Methods
2.1. Treatment planning
Treatment plans were created for an 11-year-old girl who was diagnosed with
medulloblastoma and was treated at our institution with proton CSI to 23.4 Gy. The CRT,
IMRT, and PRT treatment plans were created using a commercial treatment planning system
(TPS) (Eclipse, version 8.9; Varian Medical Systems, Palo Alto, CA). The ovaries were
delineated by a pediatric radiation oncologist on the patient’s planning computed
tomography (CT) image using contouring tools in the TPS; these are referred to hereafter as
the nominal ovaries. The anisotropic analytical algorithm was used for all photon dose
calculations and the proton convolution superposition algorithm for all proton dose
calculations. The TPS proton dose algorithm was previously validated (Newhauser et al.,
2007). The TPS photon algorithm used in this study was previously validated following the
methods of Das et al. (2008). Heterogeneity corrections were used for all dose calculations.
The treatments were planned with the patient in the supine position. The plans had a high
degree of clinical realism.
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The clinical target volume (CTV) for all three treatment plans included the entire
craniospinal fluid (CSF) space (the brain and spinal canal through the cauda equina to the
level of the S2/S3 vertebral junction [fig. 1]). The total prescribed dose was 23.4 Gy relative
biological effectiveness (St Clair et al., 2004), i.e., 21.3 Gy × 1.1 for the proton CSI
treatment plan and 23.4 Gy × 1 for the photon CSI treatment plan. We used an RBE value of
1.1 for protons following the recommendations of the International Commission on
Radiation Units and Measurements (ICRU, 2007) and in accordance with the clinical
practice for PRT at our institution. All treatment plans were reviewed and approved by a
board-certified radiation oncologist who specializes in pediatric radiotherapy.
2.1.1. CRT treatment plan—The CRT treatment plans were created following the
methods described by Howell et al. (2012). A brief summary of these methods in provided
here. At our institution, the standard of care for CRT for CSI is a field-in-field (FIF)
technique. This technique was developed using the Pinnacle TPS and uses multiple lower-
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weighted reduction fields within the primary cranial and spinal field to decrease the size of
the areas receiving the highest dose, resulting in a more conformal and homogeneous plan
for the target volume (Yom et al., 2007). Our clinical FIF technique also uses modulation to
create intrafraction field junctions. For this study, we modified our clinical FIF technique to
use with the Eclipse TPS and used two interfraction field junctions instead of two
intrafraction junctions (to simplify the treatment planning). The CRT treatment plan
included two opposed 6-MV isocentric lateral cranial fields and a 6-MV isocentric posterior
spinal field. The fields were defined, i.e., field sizes were selected and plans were
normalized to ensure full coverage of the CTV, taking into account setup uncertainties. The
width of the spinal field laterally covered the entire vertebral body with a 1-cm lateral
margin on either side. The field was laterally defined using the lower jaws of the collimator
and the multileaf collimator. The spinal field was normalized such that the 100% isodose
surface covered the spinal canal with an additional 3-mm margin anteriorly. The cranial
fields were defined such that the whole brain was irradiated, including the cervical region of
the spinal cord. For the cranial fields, the multileaf collimator was used to block the eyes
and the chin. After the initial field geometry was defined, two 0.5-cm junction shifts were
added for each of the treatment fields by changing the Y-collimator border (superior–
inferior field border) to feather the junctions between the cranial and spinal fields.
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2.1.2. IMRT treatment plan—The IMRT plan included the two FIF cranial fields
(described above) and five IMRT spinal fields. The IMRT fields were set at 140°, 160°,
180°, 200°, and 220° gantry angles, following Parker et al. (2007), to achieve coverage of
the CTV and minimize dose to normal tissues, such as the lungs, kidneys, and heart. This
arrangement minimized the volume of normal tissues through which the beams entered. A
planning target volume (PTV) was defined to achieve coverage comparable to that of the
CRT plan, namely, from T1 to the S2/S3 junction along the spinal axis and 1 cm laterally
from the vertebral bodies, with full coverage extending 3 mm anteriorly to the spinal canal.
The dose distribution was optimized using the inverse planning method. The optimization
objectives were to deliver the prescribed dose to 100% of the PTV and to minimize the
doses to normal tissues in close proximity to the target volume. For simplicity, junction
shifts were omitted for this plan because the dose distribution at the field junction area was
acceptably uniform.
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In the original IMRT plan dose constraints were not specifically applied to reduce dose to
the ovaries. Nevertheless, doses to the ovaries could potentially be decreased if they were
included during the optimization process (assuming they were within or partially within the
boundaries of the IMRT fields). To investigate the potential dose reduction that could be
achieved by optimization, IMRT plans were created avoiding each ovary in turn.
Specifically, we created an optimized IMRT plan for each set of ovaries that was within or
partially within the treatment field (sets 1, 2, and 3; ovary sets are described in more detail
below). No additional plans were created for the ovary sets that were outside the treatment
fields.
2.1.3. PRT treatment plan—The PRT treatment plans were created following the
methods of Giebeler et al. (manuscript in review), which are briefly reviewed here. In this
study (and in accordance with clinical practice at our institution), we used an age-specific
CTV for proton CSI treatment planning. For proton CSI patients treated at our institution,
the CTV includes the entire CSF space, including the brain and the spinal cord. The CTV
extended to the cauda equina to the level of the S2/S3 vertebral junction and was equivalent
to the CTV for CRT or IMRT. For patients under the age of 15 years (i.e. who have not
reached skeletal maturity), our protocol calls for an additional normal tissue target volume
(NTTV), which includes the entire vertebral bodies. The rationale for this “is to avoid sharp
dose gradients in the vertebral bodies in patients whose skeletons are still maturing” (Howell
Phys Med Biol. Author manuscript; available in PMC 2014 May 21.
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et al., 2012). Such sharp gradients could cause asymmetric growth of the vertebral body
therefore the best alternative is to irradiate the whole vertebral body uniformly in these
patients (St Clair et al., 2004; Brodin et al., 2011).
The PRT plan consisted of two opposed-lateral-oblique cranial fields, defined in the same
way as those used for the CRT plan, and two posterior–anterior spinal fields. In accordance
with ICRU recommendations (ICRU, 2007) and our clinical practice, lateral, proximal, and
distal uncertainty margins were added on a field-by-field basis to ensure adequate coverage
of the CTV (rather than using a single PTV). For this patient, the uncertainty margins were
designed such that the CTV as well as the entire vertebral bodies (NTTV) received the full
prescribed dose. The characteristics of the fields used for PRT are listed in table 1, including
proton beam energy, spread-out Bragg peak width, gantry angle, and collimator dimensions.
The treatment plan was similar to that from Taddei et al. (2010), except that two junction
shifts were added to enhance clinical realism.
2.2. Determination of dose from stray radiation
Out-of-field (stray) doses, which are caused by leakage and scatter radiation, are not
accurately calculated by the TPS for either photon or proton therapy. Instead, stray radiation
doses from CRT and IMRT were determined using an analytical model, and stray radiation
doses from PRT were calculated using Monte Carlo simulations.
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2.2.1. Stray radiation dose from CRT and IMRT—In CRT and IMRT, the main
components of stray radiation are scatter from the patient and leakage from the treatment
head. Because 6-MV beams were used (below the threshold energy for photoneutron
production), stray neutron doses for these modalities were not present. Based on direct
comparison with thermoluminescent detector measurements in an anthropomorphic
phantom, Howell et al. (2010) reported the underestimation of stray radiation dose as
function of distance from the edge of the treatment field for irradiations using the same
beam energy, linac type, and dose calculation algorithm used in this work, i.e., a 6-MV
Varian Clinac linac equipped with a Millennium multileaf collimator and the Eclipse
analytical anisotropic algorithm (AAA) dose algorithm; in fact we used the same treatment
planning computer (with the exact same 6 MV-beam model) as was used for in the study by
Howell et al. (2010). We applied a quadratic fit to the data of Howell et al. (2010) (figure 2)
to extract a formulaic relationship between underestimation of dose and distance from the
field edge. Then, we used this relationship to estimate a correction factor for the organ dose
from stray radiation as a function of the distance from the organ centroid to the edge of the
radiation field. We applied this correction factor to the stray radiation dose reported by the
TPS to obtain the corrected stray radiation dose for the CRT and IMRT plans.
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2.2.2. Stray radiation dose from PRT—Stray radiation in passively scattered PRT is
due to secondary neutrons arising from proton-induced nuclear reactions occurring in the
treatment head (external neutrons) and within the patient (internal neutrons) (Taddei et al.,
2008; Zheng et al., 2008; Agosteo et al., 2008; Perez-Andujar et al., 2009). Because the TPS
does not account for the dose from stray neutrons, we used a Monte Carlo code to calculate
that value. A model of the proton nozzle used for this patient’s treatment was previously
developed (Newhauser et al., 2007) using the Monte Carlo N-Particle eXtended (MCNPX
v2.7c ) code (Pelowitz, 2005). The treatment nozzle modeled with MCNPX was previously
benchmarked by comparison with measurements (Titt et al., 2008). To ensure that the
proton nozzle was correctly configured for the patient’s treatment, we used in-house
software (Newhauser et al., 2008) to automatically create the input files for the Monte Carlo
simulations based on the PRT treatment plan described in section 2.1.3. The commercial
TPS stores treatment plans using the standard Digital Imaging and Communications in

Phys Med Biol. Author manuscript; available in PMC 2014 May 21.

Pérez-Andújar et al.

Page 5

NIH-PA Author Manuscript

Medicine Radiotherapy (DICOM-RT) format. The in-house software used a preprocessing
code to read the DICOM-RT file for the PRT plan and parse the information needed to
create the Monte Carlo input files corresponding to each defined configuration of the proton
nozzle. This information included characteristics such as the position and dimensions of the
collimator, the size of the air gap between the end of the snout and the proximal surface of
the patient, the snout angle, the type of scatter foil, and the energy degrader used. The inhouse software also converted patient CT data from the DICOM-RT format to the Monte
Carlo input format (Taddei et al., 2009; Newhauser et al., 2009). A voxelized phantom was
used to represent the patient in the geometric model. Absorbed doses were calculated
separately for external and internal neutrons. External neutrons were defined as those
originating in the treatment head (outside the patient), whereas internal neutrons were those
originating within the patient. The neutron absorbed dose was calculated by using the Monte
Carlo code to determine the energy deposited per mass in each tissue voxel representing the
organs.
The neutron absorbed dose D was used to calculate the equivalent dose H according to:
(1)
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where w̄R is the mean radiation weighting factor for neutrons. In a previous study
(Newhauser et al., 2009), we estimated the w̄R values for internal neutrons for a child’s
proton CSI treatment for organs superior and inferior to the junction of the T8 and T9
vertebrae. We used the same w̄R value for internal neutrons as Newhauser et al. (2009) (w̄R
=9.93) and for external neutrons we used the values presented by Taddei et al. (2010) (w̄R
=9.75), as this patient’s proton CSI treatment was very similar to that of their study. In their
study w̄R was calculated as:
(2)

where Φ is the neutron spectral fluence and wR is the neutron radiation weighting factor
according to the procedure from International Commission on Radiological Protection
(ICRP) Publication 92 (ICRP, 2003) given in equation (3). w̄R depends on neutron energy
(En):
(3)
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2.3. Ratio of relative risk of premature ovarian failure
The percentage of primordial follicles killed, g(H), as a result of each treatment was
predicted on the basis of the model proposed by Wallace et al. (2005) as:
(4)

where H is the equivalent dose received by the ovaries during treatment. This model was
originally defined in terms of absorbed dose, but to compare the doses received by the
ovaries during photon and proton treatments, we used equivalent dose instead.
The RRPOF value for each modality was taken as the fraction of primordial follicles killed
(Eq. 4) by an equivalent dose H to the ovaries from the entire course of CSI, that is, the total
for both primary and stray radiation.
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The RRRPOF of photon to proton CSI was calculated for each photon modality. Specifically,
RRRPOF was defined as:
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(5)

where RRCRT, RRIMRT, and RRPRT are the relative risks associated with CRT, IMRT, and
PRT, respectively. If RRRPOF = 1, the two modalities confer an equal risk of POF. If
RRR POF > 1, then CRT and/or IMRT are associated with a higher risk of POF than PRT.
2.5. Sensitivity of RRRPOF to ovarian position
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In the study of the sensitivity of RRRPOF to ovarian position, a pediatric radiation oncologist
contoured the nominal size and position of the ovaries on the treatment planning CT images.
However, delineating the ovaries on a CT image is challenging because this organ is not
readily visualized. Thus, there was considerable uncertainty in the contoured size and
location of the ovaries. In addition, the position of the ovaries within the pelvis varies
between patients (Bardo et al., 2009). To evaluate the impact of the uncertainty in the
position of the contoured ovaries on our results, we considered several possible variations of
the ovaries’ positions. These variations were based on data reported by Bardo et al. (2009),
who examined the CT images of 174 girls and determined the positions of their ovaries with
respect to body landmarks (symphysis pubis, iliac crest, and anterior superior iliac spine).
Their study revealed complexities associated with ovarian location in young patients and
how location varies with age. Five ovary positions (in addition to the nominal position of the
ovaries) were defined for the patient in this study. These positions corresponded to the
mean, mean ± 1 standard deviation, and the extreme locations reported by Bardo et al.
(2009) for the age group that contained 11-year-old girls. The ovary positions considered are
shown in figure 3. The relative positions and the volumes of the five sets of ovaries are
presented in table 2. Each set of ovaries was contoured on four axial slices of the CT scan
(slice thickness was 2.5 mm). The total “length” of the ovaries was 1 cm, corresponding to ±
0.5 cm superior and inferior to the ovary centroid. To test the sensitivity of RRRPOF to the
position of the ovaries, we calculated RRRPOF for each of the five sets of ovaries and
compared those values with the RRRPOF values obtained using the nominal ovarian position.

3. Results
3.1. Comparison of therapeutic dose
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Figure 4 shows the dose distributions from photon and proton CSI. The prescribed dose was
delivered to 100% of the CTV for each treatment modality. Normal tissues in close
proximity to the CTV received considerably higher doses from CSI delivered with CRT than
with IMRT or PRT. Dose-volume histograms for the CTV, esophagus, heart, kidneys, liver,
and lungs are shown in figure 5. The data presented in figures 4 and 5 were taken directly
from the TPS and therefore do not include stray neutrons from PRT and underestimated
low-dose portions of the dose-volume histograms (i.e., <5% of the prescribed dose for CRT
and IMRT).
3.2. Equivalent dose delivered to ovaries at nominal positions
Equivalent doses received by the nominal ovaries from CRT, IMRT, and PRT are listed in
table 3. More specifically, the minimum, maximum, and mean equivalent doses (H) from
therapeutic radiation field reported by the TPS are shown, as well as the sum of the dose
from the TPS and the dose from stray radiation. The values are listed for therapeutic
equivalent dose only and for the sum of the therapeutic and stray components. The mean
equivalent doses, including stray equivalent doses, received by the nominal ovaries during
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CRT (0.8 Sv) was 4 times that of PRT (0.2 Sv), and that of IMRT (0.5 Sv) was 2.5 times
that of PRT. Neutrons predominated the equivalent dose delivered to structures adjacent to
the treatment fields for PRT. Figure 6 shows the neutron equivalent doses from PRT.
Equivalent doses from external neutrons ranged from 0.04 Sv to 0.4 Sv, and those from
internal neutrons ranged from 0.2 Sv to 2 Sv.
3.3. Sensitivity of RRRPOF to ovarian position
Table 4 summarizes the equivalent dose in the ovaries at different positions in the pelvis.
This table includes equivalent doses calculated by the TPS and the contributions from
therapeutic and stray radiation. The discussion below focuses on total equivalent doses. The
highest mean equivalent dose from IMRT, 5.5 Sv, was received by ovary set 1, whereas the
highest mean equivalent dose from CRT, 6.6 Sv, was received by set 2. The mean equivalent
dose in the ovaries from PRT stayed fairly constant for all sets (ranging from 0.25 Sv to 0.40
Sv). The lowest equivalent doses received by all sets of ovaries were from PRT, including
doses from internal and external neutrons. Set 3 received a slightly higher dose from PRT
than the other sets, a consequence of the proximity of this ovary set to the treatment field
edge.
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The predicted percentages of primordial follicles killed as a result of CRT, IMRT, and PRT,
taking into account both therapeutic and stray mean equivalent dose, are listed in table 5.
Our results reveal that PRT had a lower predicted RRPOF than CRT or IMRT for all sets of
ovaries, regardless of uncertainties in ovarian location.
3.4 IMRT optimization effects on RRRPOF
For these test cases in which the ovaries were considered during optimization, we found that
the dose to the ovaries could be substantially decreased (with no change in PTV coverage).
Data for these test cases are presented in figure 7, which compares the DVHs for ovary sets
1, 2, and 3 from the corresponding optimized treatment plans. The proportions of primordial
follicles predicted to be killed based on optimized IMRT plans were 39%, 47%, and 33% for
ovary sets 1, 2, and 3, respectively, a factor of 2 less than when the ovaries were not
considered during optimization. Correspondingly, the optimized plans resulted in RRRPOF
values that were decreased by a factor of 2.2, 1.6, and 1.8 for ovary sets 1, 2, and 3,
respectively.

4. Discussion and conclusion
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In this study, we quantified RRRPOF to compare three radiotherapy techniques. Our finding
that RRRPOF > 1 when comparing CRT or IMRT to PRT indicates that PRT may reduce the
risk of fertility complications relative to CRT or IMRT. We also studied the sensitivity of
RRRPOF to variations in the anatomic position of the ovaries. Our finding that RRRPOF > 1
for all the various ovary positions studied here, even when we included contributions from
external and internal neutrons, again suggests that PRT carries lower risk of these
complications.
For the patient studied here, we found that the predicted RRPOF was highest for the sets of
ovaries within the radiation field or closest to it for CRT and IMRT and that the further
away from the radiation field the ovaries were, the lower the percentage of primordial
follicles killed. Nevertheless, we cannot draw a definitive conclusion about how RRRPOF
varies with the position of the ovaries for the larger population of girls and young women
who receive CSI. In particular, patients of different ages should be studied to identify
whether there is a correlation between the position of the ovaries and RRRPOF.
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There was also some uncertainty in the true location of the ovaries because they were
delineated using the patient’s CT images. While accurate delineation of the ovaries can be
achieved by fusing the CT with a magnetic resonance image (MRI), no such images were
available for this patient. Furthermore, magnetic resonance imaging is not generally
available for CSI treatment planning because it is not routinely done at our institution (or
most other centers) for CSI treatment planning. Nevertheless, we have accounted for
uncertainty in the RRPOF that is related to uncertainty in the ovary position by considering
various possible alternative ovary positions.
The results of this study emphasize that the dose received by the ovaries varies strongly with
their proximity to the therapeutic field edge for both CRT and IMRT. However, the total
dose equivalent used a correction factor that was calculated based on the distance of the
centroid of the ovaries to the field edge, which introduced a small amount of uncertainty in
the dose equivalent. Based on the deviation of 0.5 cm between the most superior and inferior
aspects of the ovaries from the centroid, we calculated a maximum deviation of 0.7% of the
dose, which translates to a maximum uncertainty in RRRPOF of 0.9%.

NIH-PA Author Manuscript

For photon therapy, our study suggests that for patients whose ovaries are partially within
the treatment field, efforts should be made to reduce the dose to the ovaries. In particular, we
found that considering the ovaries as an avoidance structure during IMRT optimization
substantially reduced ovarian dose. However, such efforts are only possible if the true
location of the ovaries is actually known. Recently, Gay et al. (2012) recommended use of
MRI for contouring the ovaries and other reproductive organs such as the uterus, cervix, and
fallopian tubes. This study seems to confirm the importance of that recommendation and
highlights the potential role of such imaging in reducing dose to the ovaries.
There is also some uncertainly in the calculation of the equivalent dose, which depends on
the absorbed dose calculated by the TPS, the Monte Carlo simulation of stray neutron dose,
and the calculation of w̄R. The uncertainty in the in-field doses calculated by the TPS is
relatively small (about 2% based on the commissioning of the TPS) in the context of this
study. The uncertainty in the calculation of the neutron dose with MCNPX is due to the
statistical error associated with the mean equivalent dose values. This was found to be <5%
(at one standard deviation). This error is associated with the random fluctuations in the
results of the Monte Carlo code and not with the systematic uncertainty of the equivalent
dose value.
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Uncertainties in the w̄R calculation are much larger than for the other two factors and
therefore have a greater potential impact on the results of this study. Based on the large
uncertainty in w̄R, we performed a sensitivity test in order to determine the influence of w̄R
on the results shown in this work, following the approach of Newhauser et al. (2009). The
value of w̄R was varied from 5 to 50. For the nominal ovaries, protons still represent lower
RRRPOF for wR<25 when compared with CRT and IMRT. When w̄R =25 the RRRPOF for
IMRT is 0.87, showing that in this case PRT could have a higher RRRPOF. For 25< w̄R < 50,
the apparent advantage of PRT in terms of RRRPOF was diminished. We conclude that if w̄R
is truly higher than 25, then the advantage of protons in terms of dose delivered to the
ovaries could be diminished. However, the advantage of protons in sparing other normal
tissue during CSI would still exist.
Finally, for completeness, we predicted the age of ovarian failure on the basis of the dose the
ovaries received for the patient evaluated here. In the worst-case scenario, her ovaries
received an equivalent dose of 6.64 Sv. Using the model of Wallace et al. (2005), we
predicted that after radiotherapy her ovaries would have approximately the same number of
primordial follicles as the ovaries of a healthy unirradiated 35-year-old woman, which
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would lead to ovarian failure in our patient at an attained age of 26 years. Although the
uncertainties in this calculation are large and difficult to estimate, the qualitative finding
clearly strengthens the rationale to decrease RRPOF after radiotherapy by decreasing the
radiation received by the ovaries during radiotherapy. This could be done in various ways.
Unfertilized follicles could be preserved by removing them from the ovaries before
treatment, preserving them, and then reimplanting the follicles into the ovaries after
treatment. Other possibilities are performing ovarian transposition before treatment and
adding shielding during the treatment (Lee et al., 2006; Sauvat et al., 2009; Wo and
Viswanathan, 2009). However, each of these methods has some limitations. Preservation of
follicles might not be viable for very young girls, and it is an invasive procedure (Lee et al.,
2006). Ovarian transposition is also an invasive procedure, and sometimes ovarian function
is not fully recovered after transposition (Sauvat et al., 2009). Finally, some studies show
that although shielding can decrease the dose to the ovaries, they might still receive enough
dose to affect their function (Covens et al., 1996).
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An ideal radiotherapy technique would deliver the efficacious treatment without posing any
risk to the ovaries. This study presented a tool to interpret ovarian dose and may help in
making a decision about which radiotherapy technique is most suitable for treating a
particular girl or young woman, depending on ovary location and other factors. To the best
of our knowledge, this is the first in silico study to compare RRPOF between photon and
proton modalities. Numerous studies have evaluated how radiation may affect female
patients, but no prior study has determined whether predicted or observed POF is lower for a
particular radiotherapy technique. Because of ethical and other considerations, it is unlikely
that an in vivo prospective randomized trial will ever be conducted to quantify fertility
outcomes that differ with the treatment modality. Therefore, in silico studies appear to be an
attractive alternative to assess this issue. We hope that this work encourages more studies of
this kind and that more data are produced to enable a better understanding of how dose to
the ovaries and other reproductive organs are affected by the radiotherapy technique. In
addition, dosimetric measurements would be desirable to determine the exact dose received
by ovaries and to enable a better assessment of RRPOF.
In conclusion, we estimated RRRPOF for CSI using CRT, IMRT, and PRT for an 11-year-old
girl. The RRRPOF for the nominal ovaries was highest for CRT and lowest for PRT. We also
evaluated the sensitivity of RRRPOF to the position of the ovaries. We found that the RRPOF
was highest for the sets of ovaries within the radiation field for CRT and IMRT. In addition,
we found that PRT had the lowest RRPOF for the nominal ovaries as well the other ovarian
positions we evaluated.
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Figure 1.

CTV (red contour) used to compare the dose delivered to the spinal cord and the brain from
CSI using CRT, IMRT, and PRT.
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Figure 2.
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A quadratic fit was applied to the TPS underestimation data from Howell et al. (2010) as a
function of distance from the edge of the radiation field. This fit was used to estimate the
percentage by which the TPS underestimates the stray radiation dose to the ovaries for the
CRT and IMRT plans.
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Figure 3.

Digital radiograph showing the positions of the 5 sets of ovaries used to evaluate the
sensitivity of RRRPOF to ovarian position.
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Figure 4.

Dose distributions from CRT (left), IMRT (center), and PRT (right).
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Figure 5.

Dose-volume histograms to compare the CRT (a), IMRT (b), and PRT (c) plans for various
contoured organs, including the CTV, esophagus, heart, kidneys, liver, and lungs.
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Figure 6.

The neutron equivalent doses delivered during PRT, from external neutrons (left) and
internal neutrons (right).
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Figure 7.

Dose-volume histogram data for the original plan and plans optimized to spare the ovaries
Plans were optimized to spare ovary sets 1 (a), 2 (b), and, 3 (c).
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Characteristics of the fields used for proton craniospinal irradiation for an 11-year-old girl adapted from
(Taddei et al. 2010)
Characteristic

Spinal fields

Cranial fields

LPA

UPA

RPO

LPO

Pre-nozzle proton energy (MeV)

160

160

200

200

SOBP width (cm)

7

6

16

16

Gantry angle (°)

180

180

255

105

Collimated field, major axis (cm)

19.8

15.7

15.9

15.9

Collimated field, minor axis (cm)

5.0

4.8

15.2

15.2

Abbreviations: LPA, lower posterior–anterior; LPO = left posterior oblique; RPO = right posterior oblique; UPA = upper posterior–anterior; SOBP
= spread-out Bragg peak.
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Position and volume of 5 sets of ovaries used to test the sensitivity of the relative risk of premature ovarian
failure (RRRPOF) to the position of the ovaries.
Ovary seta

±x (cm)b

±y (cm)c

Volume (cm3)d

1

41.6

51.6

1030

2

63.1

62.0

1430

3

23.8

40.9

1250

4

2.5

15.2

1450

5

75.0

100.2

750

a

Positions of the ovaries are based on the data of Bardo et al. (2009).

b

x is the distance from the iliac crest of the pelvis to the superior part of the ovary.

c

y is the distance from the anterior superior iliac spine of the pelvis to the lateral part of the ovary.

d

Note that the ovaries defined here have volumes that are similar to those of the nominal ovaries.
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0.5
0.4
0

CRT

IMRT

PRT

0.002

0.6

0.7

Hmax

0.001

0.4

0.6

Hmean

0.2

0.5

0.6

Hmin + Hstray

0.3

0.8

0.9

Hmax + Hstray

0.2

0.5

0.8

Hmean + Hstray

Abbreviations: CRT = conventional photon radiotherapy; IMRT = intensity-modulated photon radiotherapy; PRT = proton radiotherapy; TPS = treatment planning system.

Hmin

Treatment modality

Equivalent dose (Sv)

Equivalent doses received by the nominal ovaries from CRT, IMRT, and PRT. The minimum, maximum, and mean equivalent doses (H) from the
therapeutic radiation field reported by the TPS are shown, as is the sum of the dose from the TPS and the dose from stray radiation.
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5.3

1.2

0.6

0.8

3

4

5

0.8

0.4

2.7

4.2

5.5

IMRT

0.001

0.001

0.06

0.001

0.001

PRT

1.01

0.77

1.50

6.64

0.60

CRT

0.80

0.50

2.70

4.20

5.50

IMRT

0.25

0.33

0.40

0.29

0.34

PRT

Therapeutic + stray

Abbreviations: CRT = conventional photon radiotherapy; IMRT = intensity-modulated photon radiotherapy; PRT = proton radiotherapy; TPS = treatment planning system.

In the calculations, we used an average value of the radiation weighting factor, w̄R = 9.75 for external neutrons and w̄R = 9.93 for internal neutrons

a

0.6

2

CRT

Therapeutic (reported by TPS)

1

Ovary set

H (Sv)a

Mean equivalent dose (H) received from CRT, IMRT, and PRT by the 5 sets of ovaries contoured for the sensitivity test. The mean equivalent dose from
therapeutic radiation reported by the TPS is shown as well as the sum of the dose from the TPS and the dose from stray radiation.

NIH-PA Author Manuscript

Table 4
Pérez-Andújar et al.
Page 23

Phys Med Biol. Author manuscript; available in PMC 2014 May 21.

NIH-PA Author Manuscript

NIH-PA Author Manuscript
85.04
76.56
60.64
15.89
24.14

18.72

89.89

40.51

23.24

29.38

1

2

3

4

5

8.40

10.57

12.96

9.38

10.98

7.71

PRT

3.50

2.18

3.13

9.58

1.71

3.00

RRRPOF

2.87

1.49

4.68

8.16

7.75

2.06

Abbreviations: CRT = conventional photon radiotherapy; IMRT = intensity-modulated photon radiotherapy; PRT = proton radiotherapy; TPS = treatment planning system.

The percentages of primordial follicles killed were calculated by using the sum of the therapeutic dose (predicted by the TPS) and the stray radiation dose

a

15.86

IMRT

23.09

CRT

Nominal

Ovary Set

Primordial follicles killed (%)a

Predicted percentage of primordial follicles killed as a result of CRT, IMRT, and PRT for the 5 sets of ovaries used in the sensitivity test. Also listed are
values of the ratio of relative risk of premature ovarian failure (RRRPOF).
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Ratio of relative risk of premature ovarian failure (RRRPOF) for w̄R sensitivity test. All values were calculated
for the nominal ovaries. w̄R was assumed to be the same for the internal and external neutrons.
w̄R

5

5.69

3.91

10

2.96

2.03

15

2.02

1.14

25

1.26

0.87

50

0.69

0.48
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